rubitecan has been researched along with Liver Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Pan, J; Qing, C; Sun, Y; Tian, Y; Zhang, Y; Zhou, H; Zhu, Q | 1 |
| Chang, S; Chen, Z; Gu, Z; He, B; Lu, J; Nie, Y; Xie, L; Zheng, S; Zou, S | 1 |
| Gilbert, BE; Huaringa, A; Knight, V; Loyer, E; Newman, RA; Verschraegen, CF; Walsh, G | 1 |
| Khaoustov, VI; Krishnan, B; Mearns, M; Noda, A; Ozer, A; Slagle, BL; Smith, JR; Yoffe, B | 1 |
1 trial(s) available for rubitecan and Liver Neoplasms
| Article | Year |
|---|---|
Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Liposomes; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Time Factors; Topoisomerase Inhibitors | 2004 |
3 other study(ies) available for rubitecan and Liver Neoplasms
| Article | Year |
|---|---|
9-Nitro-20(S)-carbonate-camptothecin (NCP4), a novel prodrug of 9-nitrocamptothecin (9-NC), exhibits potent chemotherapeutic efficacy and improved safety against hepatocarcinoma.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carbonates; Carcinoma, Hepatocellular; Humans; Lactones; Liver Neoplasms; Mice; Prodrugs | 2022 |
Characterization of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Stability; Female; Gene Expression Regulation, Neoplastic; Humans; Liposomes; Liver Neoplasms; Mice; Solubility; Ultrasonics; Water; Xenograft Model Antitumor Assays | 2011 |
Induction of senescent cell-derived inhibitor of DNA synthesis gene, SDI1, in hepatoblastoma (HepG2) cells arrested in the G2-phase of the cell cycle by 9-nitrocamptothecin.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Hepatocellular; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA; G2 Phase; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1995 |